Jemperli (dostarlimab)

pCPA File Number: 23163

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

PC0381-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable